APOE and Alzheimer disease: The task was administered to apolipoprotein (APOE) ε4 allele carriers, of whom almost half develop Alzheimer’s disease by the average age of 76, compared to only 20% of non-carriers who convert to Alzheimer’s disease by the average age of 84 [19].